MEDNYSEMiscellaneous Food Preparations & Kindred ProductsFiscal year ends December 31
MEDIFAST INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$12.03+0.15 (+1.26%)
Close on Oct 19, 2026
- Market cap
- $133.95M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
71.3%−3.3 pts over 5 years
Operating margin
-3.7%−18.0 pts over 5 years
Net margin
-4.8%−15.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -36.0% | -37.7% | -16.2% | +3.5% | |
| Gross profit | -38.1% | -37.7% | -17.0% | +3.2% | |
| Free cash flow | -92.7% | -80.9% | -61.0% | -26.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 19.3% | 78.5% | -9.1% | |
| Return on assets | 15.0% | 43.7% | -7.0% | |
| Current ratio | 4.15 | 2.10 | 4.69 | |
| Inventory turnover | 4.4× | 4.6× | 3.5× | |
| Capex to revenue | 1.0% | 0.6% | 1.5% | |
| Diluted shares | 12M | 12M | 11M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Medifast generated $468.11M from operations and spent $465.89M on capital expenditure, dividends and share buybacks. 15% of that went back into the business.
Generated
$468.11M
Used
$465.89M
Capital expenditure$70.44M15%Dividends$209.40M45%Share buybacks$186.05M40%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.8%
×Asset turnover1.45×
×Equity multiplier1.30×
=Return on equity, FY2025-9.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4.8% | 1.45× | 1.30× | -9.1% |
| FY2024 | 0.3% | 2.03× | 1.44× | 1.0% |
| FY2023 | 9.3% | 3.42× | 1.76× | 55.8% |
| FY2022 | 9.0% | 4.47× | 2.00× | 80.3% |
| FY2021 | 10.7% | 4.53× | 1.87× | 91.2% |
| FY2020 | 11.0% | 3.97× | 1.80× | 78.5% |
| FY2019 | 10.9% | 3.92× | 1.70× | 72.8% |
| FY2018 | 11.1% | 3.18× | 1.46× | 51.7% |
| FY2017 | 9.2% | 2.26× | 1.32× | 27.4% |
| FY2016 | 6.5% | 2.31× | 1.29× | 19.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$18.67M
- Cash generatingOperating cash flow above zero$6.86M
- Return on assets improvedROA up on the prior year0.7% → -6.6%
- Earnings backed by cashOperating cash flow above net income$6.86M vs -$18.67M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.34 → 4.69
- No dilutionShare count did not rise11M → 11M
- Gross margin improvedGross margin up on the prior year73.80% → 71.33%
- More efficientAsset turnover rose1.94 → 1.36